Literature DB >> 27757499

[Neoadjuvant short-term radiotherapy followed by FOLFOX chemotherapy : No standard treatment for rectal cancer].

David Krug1, Matthias F Häfner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27757499     DOI： 10.1007/s00066-016-1061-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.

Authors:  K Bujko; M P Nowacki; A Nasierowska-Guttmejer; W Michalski; M Bebenek; M Kryj
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

2.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila
Journal:  Lancet Oncol       Date:  2015-07-14       Impact factor: 41.316

3.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Authors:  Claus Rödel; Ullrich Graeven; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Dirk Arnold; Ralf-Dieter Hofheinz; Michael Ghadimi; Hendrik A Wolff; Marga Lang-Welzenbach; Hans-Rudolf Raab; Christian Wittekind; Philipp Ströbel; Ludger Staib; Martin Wilhelm; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer; Torsten Liersch
Journal:  Lancet Oncol       Date:  2015-07-15       Impact factor: 41.316

Review 4.  Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.

Authors:  Anne J Breugom; Marloes Swets; Jean-François Bosset; Laurence Collette; Aldo Sainato; Luca Cionini; Rob Glynne-Jones; Nicholas Counsell; Esther Bastiaannet; Colette B M van den Broek; Gerrit-Jan Liefers; Hein Putter; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

5.  Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.

Authors:  Yanhong Deng; Pan Chi; Ping Lan; Lei Wang; Weiqing Chen; Long Cui; Daoda Chen; Jie Cao; Hongbo Wei; Xiang Peng; Zonghai Huang; Guanfu Cai; Ren Zhao; Zhongcheng Huang; Lin Xu; Hongfeng Zhou; Yisheng Wei; Hao Zhang; Jian Zheng; Yan Huang; Zhiyang Zhou; Yue Cai; Liang Kang; Meijin Huang; Junsheng Peng; Donglin Ren; Jianping Wang
Journal:  J Clin Oncol       Date:  2016-08-01       Impact factor: 44.544

6.  Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

Authors:  Deborah Schrag; Martin R Weiser; Karyn A Goodman; Mithat Gonen; Ellen Hollywood; Andrea Cercek; Diane L Reidy-Lagunes; Marc J Gollub; Jinru Shia; Jose G Guillem; Larissa K F Temple; Philip B Paty; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

7.  Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases.

Authors:  Sang Joon Shin; Hong In Yoon; Nam Kyu Kim; Kang Young Lee; Byung Soh Min; Joong Bae Ahn; Ki Chang Keum; Woong Sub Koom
Journal:  Radiat Oncol       Date:  2011-08-24       Impact factor: 3.481

8.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

Authors:  Samuel Y Ngan; Bryan Burmeister; Richard J Fisher; Michael Solomon; David Goldstein; David Joseph; Stephen P Ackland; David Schache; Bev McClure; Sue-Anne McLachlan; Joseph McKendrick; Trevor Leong; Cris Hartopeanu; John Zalcberg; John Mackay
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

9.  Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer.

Authors:  D Pettersson; E Lörinc; T Holm; H Iversen; B Cedermark; B Glimelius; A Martling
Journal:  Br J Surg       Date:  2015-07       Impact factor: 6.939
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.